Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast].

IF 3.9 Q2 ONCOLOGY
Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2025-07-02 eCollection Date: 2025-01-01 DOI:10.2147/BLCTT.S549780
Amer M Zeidan, Courtney DiNardo
{"title":"Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast].","authors":"Amer M Zeidan, Courtney DiNardo","doi":"10.2147/BLCTT.S549780","DOIUrl":null,"url":null,"abstract":"<p><p>This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1 inhibitors. The analysis examines critical factors including treatment sequencing, combination regimens, and toxicity management, particularly the monitoring and mitigation of differentiation syndrome and QT interval prolongation. Emphasis is placed on the clinical rationale for individualized therapy selection and the importance of repeat mutation testing at diagnosis and relapse to guide treatment decisions. The results obtained from these clinical trials provide evidence that integrating oral targeted agents into the management of relapsed or refractory AML improves patient outcomes, especially for older or unfit patients who cannot undergo intensive chemotherapy. In conclusion, the episode demonstrates that the evolving use of IDH1 inhibitors, supported by rigorous clinical evidence, represents a promising advance in AML treatment by offering more precise, effective, and tolerable therapeutic options.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"15 ","pages":"77-83"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235440/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood and Lymphatic Cancer-Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BLCTT.S549780","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies. Through discussion of key findings from pivotal clinical trial studies, including data supporting the use of these agents in both newly diagnosed and relapsed or refractory (R/R) settings, the episode highlights significant outcomes such as increased overall response and prolonged duration of remission in patients treated with IDH1 inhibitors. The analysis examines critical factors including treatment sequencing, combination regimens, and toxicity management, particularly the monitoring and mitigation of differentiation syndrome and QT interval prolongation. Emphasis is placed on the clinical rationale for individualized therapy selection and the importance of repeat mutation testing at diagnosis and relapse to guide treatment decisions. The results obtained from these clinical trials provide evidence that integrating oral targeted agents into the management of relapsed or refractory AML improves patient outcomes, especially for older or unfit patients who cannot undergo intensive chemotherapy. In conclusion, the episode demonstrates that the evolving use of IDH1 inhibitors, supported by rigorous clinical evidence, represents a promising advance in AML treatment by offering more precise, effective, and tolerable therapeutic options.

深入研究靶向治疗:了解idh1突变AML治疗[播客]。
本播客回顾了IDH1突变型急性髓性白血病(AML)治疗的最新进展,重点关注已批准的IDH1抑制剂的机制、疗效和安全性。目的是介绍专家的见解和关键试验的临床数据,强调这些靶向治疗的临床益处。通过讨论关键临床试验研究的关键发现,包括支持在新诊断和复发或难治性(R/R)情况下使用这些药物的数据,这一事件强调了重要的结果,如使用IDH1抑制剂治疗的患者的总体反应增加和缓解持续时间延长。分析检查了关键因素,包括治疗顺序、联合方案和毒性管理,特别是监测和缓解分化综合征和QT间期延长。重点是个体化治疗选择的临床依据,以及在诊断和复发时进行重复突变检测以指导治疗决策的重要性。从这些临床试验中获得的结果提供了证据,证明将口服靶向药物整合到复发或难治性AML的管理中可以改善患者的预后,特别是对于不能接受强化化疗的老年或不适合的患者。总之,这一事件表明,在严格的临床证据支持下,IDH1抑制剂的不断发展,通过提供更精确、有效和耐受的治疗选择,代表了AML治疗的一个有希望的进步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
7.10%
发文量
16
审稿时长
16 weeks
期刊介绍: Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信